Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Leukapheresis × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Other hematologic neoplasm 1 Lymphoid 1 CNS 1

Conditions

Lymphoma, Large B-Cell, Diffuse 13 Lymphoma, Non-Hodgkin 12 Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Leukemia, Lymphocytic, Chronic, B-Cell 9 Lymphoma, Mantle-Cell 8 Lymphoma, Follicular 8 Lymphoma, B-Cell 7 Lymphoma 7 Hodgkin Disease 6 Burkitt Lymphoma 5 Lymphoma, B-Cell, Marginal Zone 4 Waldenstrom Macroglobulinemia 3 Multiple Myeloma 3 Lymphoma, Large-Cell, Anaplastic 3 Leukemia 3 Sezary Syndrome 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Myeloproliferative Disorders 2 Myelodysplastic Syndromes 2 Mycosis Fungoides 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma, T-Cell 2 Lymphoma, Large-Cell, Immunoblastic 2 Lymphoma, Extranodal NK-T-Cell 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Immunoblastic Lymphadenopathy 2 Recurrence 1 Leukemia, Prolymphocytic, B-Cell 1 Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 91 Rituximab 73 Peripheral Blood Stem Cell Transplantation 38 fludarabine phosphate 37 fludarabine 36 Filgrastim 32 Lenalidomide 31 Radiotherapy 28 Busulfan 28 Methotrexate 27 Etoposide 27 Cyclosporine 27 Melphalan 26 Cytarabine 26 venetoclax 25 Mycophenolic Acid 25 Dexamethasone 23 Bendamustine Hydrochloride 22 Antilymphocyte Serum 22 ibrutinib 21 Gemcitabine 21 Whole-Body Irradiation 19 Vincristine 18 Tacrolimus 16 Methylprednisolone 16 pembrolizumab 15 Doxorubicin 15 Brentuximab Vedotin 15 Bortezomib 15 Cord Blood Stem Cell Transplantation 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02431988 2023-04-28

COBALT

University College, London

Phase 1 Completed

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡